{"result": "(\"entity\"<|>GLYCOGENESIS<|>EVENT<|>Glycogenesis is the process of synthesizing glycogen from glucose, which can be disrupted in glucogenosis disorders.)\n##\n(\"entity\"<|>GLYCOGENOLYSIS<|>EVENT<|>Glycogenolysis is the breakdown of glycogen to glucose, a process that can be impaired in glucogenosis conditions.)\n##\n(\"entity\"<|>ACIDOSIS<|>EVENT<|>Acidosis is a condition characterized by an excess of acid in the body fluids, which can occur in metabolic disorders including glucogenosis.)\n##\n(\"entity\"<|>HYPERTRANSAMINASEMIA<|>EVENT<|>Hypertransaminasemia refers to elevated levels of transaminases in the blood, often seen in liver diseases including glucogenosis.)\n##\n(\"entity\"<|>HEPATOCARCINOMAS<|>EVENT<|>Hepatocarcinomas are liver cancers that can develop as a complication of chronic liver diseases, including those associated with glucogenosis.)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>GLYCOGENESIS<|>Glycogenesis is a metabolic process that can be disrupted in glucogenosis, leading to abnormal glycogen storage<|>7)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>GLYCOGENOLYSIS<|>Glycogenolysis is another metabolic process affected in glucogenosis, impacting glucose availability<|>7)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>ACIDOSIS<|>Acidosis can be a metabolic consequence of glucogenosis due to impaired metabolic pathways<|>6)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>HYPERTRANSAMINASEMIA<|>Hypertransaminasemia can occur in patients with glucogenosis due to liver involvement<|>6)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>HEPATOCARCINOMAS<|>Chronic glucogenosis can increase the risk of developing hepatocarcinomas due to liver damage<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: aciones de\n       todos los casos salvo en la argininemia, ya que                   emergencia, es preciso asegurar la vía aérea, incluso\n---\n                                                 Tema 18.     Soporte nutricional en metabolopatías de los aminoácidos…                    317\n\n\n\ncon ventilación mecánica; controlar también la presión                      6.2.   Manifestaciones clínicas\nintracraneal. Se debe aportar suero glucosado al 10%                          El prototipo de glucogenosis hepática es la gluco-\na un ritmo de 5-6 ml/kg/h y añadir lípidos intravenos-                      genosis tipo I, que se manifiesta principalmente por\nsos hasta conseguir un aporte de 80 kcal/kg/día, sin                        hipoglucemias y hepatomegalia. Las hipoglucemias\nadministrar proteínas las primeras 48 horas; si se tole-                    (sin hiperinsulinismo) pueden ser graves y su control\nra, administrar los nutrientes vía enteral. Reintroducir                    es el principal objetivo del tratamiento nutricional.\nlas proteínas desde 0,25-0,5 g/kg/día cuando la amo-                        La hepatopatía se caracteriza por el acúmulo del\nniemia < 100 μmol/l. Se realizará diálisis o hemofiltra-                    glucógeno y esteatosis, pero no evoluciona a cirro-\ncion (NO exsanguinotransfusión) para eliminar el amo-                       sis hepática aunque sí cursa con hipertransaminase-\nnio si este supera los 350 μmol/l.                                          mia; durante la segunda y tercera décadas de la vida\n   Se puede administrar benzoato y fenilacetato, am-                        aparecen adenomas hepáticos que pueden maligni-\nbos a dosis de 250 mg/kg/día en niños y 5,5 g/m2 en                         zarse a hepatocarcinomas29 . Las hipoglucemias son\nmayores, diluidos en sueros glucosados, al que se                           comunes a todas las formas hepáticas de glucoge-\ndebe añadir potasio, por las pérdidas, pero no sodio,                       nosis, si bien la gravedad de las mismas, la mejoría\npues ya lo aportan estos fármacos; una vez estabili-                        con la edad y las horas de tolerancia al ayuno varían\nzados, con amonio 100-200 μmol/l, e ingesta reanu-                          de un tipo a otro, siendo más grave en general el\ndada, se pueden dar por vía oral. Arg se administra                         tipo I.\npor vía parenteral a dosis de 400-600 mg/kg/día en                            Otros síntomas que pueden acompañar a la gluco-\ndeficiencia de ASS o ASL o si no se sabe tipo de                            genosis de tipo I, y al resto de las hepáticas de forma\ndeficiencia y 200 mg/kg/día en deficiencia de OTC o                         variable, son: retraso del crecimiento, retraso puberal,\nCPS.    Está   indicado      el  aporte    de   citrulina   enteral         cara de muñeca, nefromegalia que puede ir asociada a\n(150-200 mg/kg/día) en neonatos con deficiencia de                          proteinuria e insuficiencia renal, hiperlipemia, hiperlac-\nOTC o CPS (NO en deficiencia de ASS o ASL). No                              tacidemia y acidosis metabólica29.\nemplear valproico ni fenobarbital para las convulsio-                         Otros tipos de glucogenosis pueden llevar asocia-\nnes, pues disminuye la actividad del ciclo de la urea.                      da miopatía y cardiopatía (III), neutropenia, aftas e\nLa carnitina se aporta a dosis de 100-200 mg/kg/día                         infecciones     (Ib)   o  neuropatía      (IV).   La  clínica  que\ndurante las crisis hiperamoniémicas, por incremento                         acompaña a cada tipo de glucogenosis se resume en\nde su consumo y por mejorar la situación metabólica                         la tabla 8.\ny la tolerancia al benzoato.\n\n\n\n6.   Glucogenosis                                                           6.3.   Diagnóstico y control\n6.1.   Consideraciones generales                                              Debe sospecharse una glucogenosis hepática ante\n                                                                            un niño con hipoglucemia de ayuno sin hiperinsulinis-\n   Las glucogenosis o enfermedades del depósito de                          mo, pudiendo existir acidosis láctica. Si se realiza un\nglucógeno son un conjunto de enfermedades ocasio-                           test de glucagón, la respuesta de la glucemia es escasa\nnadas por una alteración en la síntesis (glucogénesis) o                    o nula y puede aumentar la acidosis láctica en el caso\nen la degradación (glucogenólisis) del glucógeno o en                       de la glucogenosis de tipo I, pudiendo diferir en otras.\nla glucólisis,\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GLUCOGENOSIS<|>EVENT<|>Glucogenosis refers to a group of diseases caused by an alteration in the synthesis or degradation of glycogen, leading to various metabolic issues.)\n##\n(\"entity\"<|>ASS<|>ORGANIZATION<|>ASS is an enzyme involved in the urea cycle, and its deficiency can lead to metabolic disorders.)\n##\n(\"entity\"<|>ASL<|>ORGANIZATION<|>ASL is an enzyme that plays a role in the urea cycle, and its deficiency can result in metabolic complications.)\n##\n(\"entity\"<|>OTC<|>ORGANIZATION<|>OTC is an enzyme that is crucial for the urea cycle, and its deficiency can lead to hyperammonemia and other metabolic issues.)\n##\n(\"entity\"<|>CPS<|>ORGANIZATION<|>CPS is an enzyme involved in the urea cycle, and its deficiency can cause severe metabolic disorders.)\n##\n(\"entity\"<|>BENZOATE<|>ORGANIZATION<|>Benzoate is a compound used in the treatment of hyperammonemia, often administered in conjunction with other therapies.)\n##\n(\"entity\"<|>PHENYLACETATE<|>ORGANIZATION<|>Phenylacetate is a compound used to manage hyperammonemia, particularly in patients with urea cycle disorders.)\n##\n(\"entity\"<|>CARNITINE<|>ORGANIZATION<|>Carnitine is a nutrient that is often supplemented during hyperammonemic crises to improve metabolic status.)\n##\n(\"entity\"<|>HYPERAMMONEMIA<|>EVENT<|>Hyperammonemia is a condition characterized by elevated levels of ammonia in the blood, often requiring urgent medical intervention.)\n##\n(\"entity\"<|>HYPOGLYCEMIA<|>EVENT<|>Hypoglycemia is a condition of abnormally low blood sugar levels, which can be a symptom of various metabolic disorders including glucogenosis.)\n##\n(\"entity\"<|>HEPATOMEGALY<|>EVENT<|>Hepatomegaly refers to the enlargement of the liver, which can occur in various metabolic disorders including glucogenosis type I.)\n##\n(\"entity\"<|>NEPHROMEGALY<|>EVENT<|>Nephromegaly is the enlargement of the kidneys, which can be associated with certain metabolic disorders.)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>ASS<|>ASS deficiency can lead to specific types of glucogenosis, affecting the metabolism of amino acids and ammonia<|>7)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>ASL<|>ASL deficiency can result in metabolic disorders classified under glucogenosis, impacting glycogen metabolism<|>7)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>OTC<|>OTC deficiency is a type of metabolic disorder that can be categorized under glucogenosis, affecting ammonia levels<|>7)\n##\n(\"relationship\"<|>GLUCOGENOSIS<|>CPS<|>CPS deficiency can lead to metabolic issues that fall under the category of glucogenosis<|>7)\n##\n(\"relationship\"<|>HYPERAMMONEMIA<|>BENZOATE<|>Benzoate is used as a treatment for hyperammonemia, helping to reduce ammonia levels in the blood<|>8)\n##\n(\"relationship\"<|>HYPERAMMONEMIA<|>PHENYLACETATE<|>Phenylacetate is administered to manage hyperammonemia, particularly in patients with urea cycle disorders<|>8)\n##\n(\"relationship\"<|>HYPERAMMONEMIA<|>CARNITINE<|>Carnitine is supplemented during hyperammonemic crises to improve metabolic status and support treatment<|>8)\n##\n(\"relationship\"<|>HYPOGLYCEMIA<|>GLUCOGENOSIS<|>Hypoglycemia is a common manifestation of glucogenosis, particularly in type I<|>6)\n##\n(\"relationship\"<|>HEPATOMEGALY<|>GLUCOGENOSIS<|>Hepatomegaly is a characteristic feature of glucogenosis type I, resulting from glycogen accumulation<|>6)\n##\n(\"relationship\"<|>NEPHROMEGALY<|>GLUCOGENOSIS<|>Nephromegaly can be associated with glucogenosis, particularly in cases involving metabolic disturbances<|>6)\n<|COMPLETE|>"}]}